Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat

RegulatoryapprovedCIFBEZYPositive

AI Analysis

Summary

Acurx Pharmaceuticals received FDA conditional acceptance of the brand name CIFBEZY and USPTO trademark allowance for its lead product candidate ibezapolstat. These regulatory milestones establish the commercial identity for the drug.

Outcome Details

FDA conditional acceptance of brand name CIFBEZY and USPTO trademark allowance

Importance:5/10

Sentiment:

0.70

FDA approvalbrandingtrademarkregulatory milestone

Read the original article

Published by PR Newswire Biotech on August 17, 2026 12:01 PM

Read Original